Last reviewed · How we verify

NCT05162339

Inflammatory Bowel Disease and Thromboembolic Events

Completed Last updated 17 December 2021
What this trial tests

trial testing No intervention was made in Inflammatory Bowel Diseases in 149 participants. Completed in 30 April 2020.

Timeline
1 November 2016
Primary endpoint
30 April 2020
30 April 2020

Quick facts

Lead sponsorCentro Hospitalar Tondela-Viseu
StatusCompleted
Study typeOBSERVATIONAL
Enrollment149
Start date1 November 2016
Primary completion30 April 2020
Estimated completion30 April 2020
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Centro Hospitalar Tondela-Viseu

Who can join

18 and older, any sex, with Inflammatory Bowel Diseases or Thromboembolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective was to demonstrate the existence and importance of hypercoagulability in patients with IBD, by determining the prevalence of changes in coagulation parameters and evaluating the impact of these changes on the occurrence of thromboembolic events.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Inflammatory bowel disease and thromboembolic events: a c'lot to learn.
    Carvalho AC, Pinho J, Cancela E, Vieira HM, et al · · 2022 · cited 5× · PMID 35651649 · DOI 10.1177/17562848221100626

Verify or expand the search:

Other trials of No intervention was made

Trials testing the same drug.

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

Other Centro Hospitalar Tondela-Viseu trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05162339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing